EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial

Prithviraj Bose iD, Haris Ali iD, Haifa Kathrin Al-Ali, Valentin Garcia-Gutierrez iD, Sebastian Grosicki iD, Zhanet Grudeva-Popova iD, Claire Harrison iD, Junshik Hong iD, Hsin-An Hou iD, Michal Kwiatek, Michael Loschi iD, Francesco Passamonti iD und 13 weitere

Journal of Clinical Oncology · 2026

DOI: 10.1200/jco-26-01080 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2026. Verfasst von Prithviraj Bose und 24 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Pyrazoles, Triazoles, Hydrazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Ruxolitinib improves splenomegaly and symptoms in myelofibrosis (MF) but lacks reliable clonal burden reduction. Selinexor, an oral inhibitor of exportin 1, has demonstrated activity in MF. We evaluated selinexor plus ruxolitinib versus ruxolitinib alone in Janus kinase inhibitor–naïve MF. METHODS In this double-blind, phase III trial, patients were randomly assigned (2:1) to receive selinexor plus ruxolitinib or placebo plus ruxolitinib. Coprimary end points were spleen volume reduction ≥35% (SVR35) and absolute mean change in total symptom score (AbsTSS; excluding fatigue) from baseline to week 24. RESULTS A total of 353 patients were randomly assigned. At week 24, SVR35 was achieved in 49.8% of the selinexor plus ruxolitinib group versus 28.0% of the placebo plus ruxolitinib group (difference, 21.8 percentage points; odds ratio, 2.58 [95% CI, 1.60 to 4.17]; P < .0001). Differences were evident by week 12 and through week 36. The AbsTSS coprimary end point was not met; however, symptom scores improved from baseline in both groups (−9.9 selinexor plus ruxolitinib, −10.9 placebo plus ruxolitinib), with no significant between-group difference. At a median follow-up of approximately 12 months, the overall survival (OS) hazard ratio was 0.43 ([95% CI, 0.19 to 1.00]; nominal P = .022). Grade ≥3 adverse events (AEs) occurred in 70.1% and 50.0% of patients in the selinexor plus ruxolitinib or placebo plus ruxolitinib groups, respectively, most commonly anemia, thrombocytopenia, and neutropenia. Nausea was more frequent with selinexor but predominantly low-grade and early. CONCLUSION In patients with JAK inhibitor–naïve MF, selinexor plus ruxolitinib met its coprimary end point of improved SVR35 but did not meet the AbsTSS coprimary end point, compared with placebo plus ruxolitinib. An early OS difference was observed. The safety profile was consistent with known AE profiles of the individual agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisPyrazolesTriazolesHydrazinesAntineoplastic Combined Chemotherapy ProtocolsHumansNitrilesPyrimidinesFemaleDouble-Blind MethodMaleAgedMiddle AgedJanus Kinase Inhibitors

Substanzen

NitrilesruxolitinibPyrimidinesPyrazolesTriazolesHydrazinesselinexorJanus Kinase Inhibitors

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, TX.
  • City of Hope, Duarte, CA.
  • Krukenberg Cancer Center Halle, University Hospital Halle (Saale), Halle, Germany.
  • Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
  • Department of Cancer Prevention, Medical University of Silesia, Katowice, Poland.
  • Medical University of Plovdiv, Plovdiv, Bulgaria.

ORCID-Profile: Prithviraj Bose, Haris Ali, Valentin Garcia-Gutierrez, Sebastian Grosicki, Zhanet Grudeva-Popova, Claire Harrison, Junshik Hong, Hsin-An Hou, Michael Loschi, Francesco Passamonti, Andrea Patriarca, Nikolai Podoltsev, Yi Chai, Amama Sadiq, Pankit Vachhani, John Mascarenhas

Förderung

  • NCI NIH HHS

Zitieren

APA

Bose, P., Ali, H., Al-Ali, H. K., Garcia-Gutierrez, V., Grosicki, S., Grudeva-Popova, Z., Harrison, C., Hong, J., Hou, H. A., Kwiatek, M., Loschi, M., Passamonti, F., Patriarca, A., Podoltsev, N., Rampal, R., Tantravahi, S., Urian, L. G., Chai, Y., Taverna, P., …, & SENTRY Trial Investigators (2026). Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-26-01080

Vancouver

Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, et al. Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial. Journal of Clinical Oncology. 2026. doi:10.1200/jco-26-01080

BibTeX
@article{Bose2026,
  author = {Bose, Prithviraj and Ali, Haris and Al-Ali, Haifa Kathrin and Garcia-Gutierrez, Valentin and Grosicki, Sebastian and Grudeva-Popova, Zhanet and Harrison, Claire and Hong, Junshik and Hou, Hsin-An and Kwiatek, Michal and Loschi, Michael and Passamonti, Francesco and Patriarca, Andrea and Podoltsev, Nikolai and Rampal, Raajit and Tantravahi, Srinivas and Urian, Laura Gabriela and Chai, Yi and Taverna, Pietro and Mark, Tomer and Sadiq, Amama and Rangwala, Reshma and Vachhani, Pankit and Mascarenhas, John and SENTRY Trial Investigators, SENTRY Trial Investigators},
  title = {Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  doi = {10.1200/jco-26-01080}
}
Kostenlos starten →